On 1 August 2025, the Korea Biomedical Review reported that Boryung launched Samsung Bioepis’ denosumab biosimilar (Xbryk™) in the Korean market, following its regulatory approval in May 2025. Xbryk™ is a biosimilar to Amgen’s Xgeva® and is approved to prevent skeletal complications in patients with bone metastases and to treat giant cell tumour of bone.
Samsung Bioepis and Boryung announced on 2 July 2025 that they entered into an exclusive licensing deal in relation to Xbryk™, one day after Samsung Bioepis and Hanmi Pharmaceuticals announced their joint South Korean launch of Samsung Bioepis’ Obodence™, biosimilar to Amgen’s Prolia® (denosumab).
Celltrion’s Stoboclo® and Osenvelt® were the first denosumab biosimilars to be approved in Korea (November 2024). In March 2025, Daewoong Pharmaceutical launched Celltrion’s Stoboclo® in Korea at a 28% discount to reference product Prolia®. Celltrion entered into a joint sales agreement with Daewoong in October 2024, under which the two companies jointly promote Celltrion’s denosumab biosimilars in Korea.